The estimated Net Worth of Mangini Siobhan Nolan is at least 1.22 百万$ dollars as of 16 February 2020. Ms Nolan owns over 83,925 units of Ngm Biopharmaceuticals Inc stock worth over 729,675$ and over the last 8 years she sold NGM stock worth over 131,848$. In addition, she makes 355,445$ as CFO and Principal Financial & Accounting Officer at Ngm Biopharmaceuticals Inc.
Sign up
Ms Mangini NGM stock SEC Form 4 insiders trading
Ms has made over 35 trades of the Ngm Biopharmaceuticals Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently she exercised 83,925 units of NGM stock worth 129,245$ on 16 February 2020.
The largest trade she's ever made was exercising 86,424 units of Ngm Biopharmaceuticals Inc stock on 16 November 2019 worth over 133,093$. On average, Ms trades about 17,037 units every 28 days since 2016. As of 16 February 2020 she still owns at least 473,815 units of Ngm Biopharmaceuticals Inc stock.
You can see the complete history of Ms Nolan stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Ms. Siobhan Nolan Mangini biography
Siobhan Nolan Mangini is the CFO and Principal Financial & Accounting Officer at Ngm Biopharmaceuticals Inc.
What is the salary of Ms Mangini?
As the CFO and Principal Financial & Accounting Officer of Ngm Biopharmaceuticals Inc, the total compensation of Ms Mangini at Ngm Biopharmaceuticals Inc is 355,445$. There are 7 executives at Ngm Biopharmaceuticals Inc getting paid more, with David Woodhouse having the highest compensation of 2,092,150$.
How old is Ms Mangini?
Ms Mangini is 40, she's been the CFO and Principal Financial & Accounting Officer of Ngm Biopharmaceuticals Inc since . There are 16 older and 1 younger executives at Ngm Biopharmaceuticals Inc. The oldest executive at Ngm Biopharmaceuticals Inc is David Goeddel, 68, who is the Lead independent director.
What's Ms Mangini's mailing address?
Mangini's mailing address filed with the SEC is C/O ALIGHT, INC., 4 OVERLOOK PT, LINCOLNSHIRE, IL, 60069.
Insiders trading at Ngm Biopharmaceuticals Inc
Over the last 5 years, insiders at Ngm Biopharmaceuticals Inc have traded over 9,159,599$ worth of Ngm Biopharmaceuticals Inc stock and bought 18,889,291 units worth 177,396,366$ . The most active insiders traders include Peter Svennilson、David V Goeddel、Group L P Svennilson Peter .... On average, Ngm Biopharmaceuticals Inc executives and independent directors trade stock every 9 days with the average trade being worth of 171,092$. The most recent stock trade was executed by Group L Ptcg Opportunity Ii... on 15 November 2023, trading 22,631 units of NGM stock currently worth 15,615$.
What does Ngm Biopharmaceuticals Inc do?
ngm bio is a research-driven, clinical stage biopharmaceutical company with a drug discovery platform designed to generate a pipeline of first-in-class biologic drug candidates. our initial r&d focus has been on cardio-metabolic and liver disease, but we believe that our research expertise – comprehensive and grounded in fundamental, interrelated mechanisms of human biology – is capable of driving the development of new therapies for a wide range of disease areas such as cancer. ngm bio’s comprehensive approach to drug discovery focuses on elucidating the biology of hormones, cell receptors and associated ligands. as we investigate these novel biological mechanisms, we assemble a deep understanding of the relationship between the structure and function of proteins of interest. coupled with our experience in protein and antibody engineering, our approach enables the efficient and targeted generation of potential first-in-class therapeutics with optimized pharmacologic profiles. work
What does Ngm Biopharmaceuticals Inc's logo look like?
Complete history of Ms Nolan stock trades at Castlight Health Inc、Ngm Biopharmaceuticals Inc、Alight
Ngm Biopharmaceuticals Inc executives and stock owners
Ngm Biopharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
David Woodhouse,
Chief Executive Officer, Director -
Jin-Long Chen,
Founder, Chief Scientific Officer, Director -
William Rieflin,
Executive Chairman of the Board of Directors -
Suzanne Hooper,
Independent Director -
Dr. David J. Woodhouse Ph.D.,
CEO & Director -
Dr. Jin-Long Chen Ph.D.,
Founder, Chief Scientific Officer & Director -
Shelly Guyer,
Independent Director -
Siobhan Nolan Mangini,
CFO and Principal Financial & Accounting Officer -
McHenry Tichenor,
Independent Director -
David Goeddel,
Lead independent director -
David Schnell,
Independent Director -
Mark Leschly,
Independent Director -
William J. Rieflin J.D.,
Exec. Chairman of Directors -
Siobhan Mangini,
Chief Financial Officer -
Carole Ho,
Independent Director -
Hsiao Lieu,
Senior Vice President, Chief Medical Officer -
Marc Learned,
Vice President - Research Operations -
Hui Tian,
Senior Vice President - Research -
Wenyan Shen,
Senior Vice President - Biologics and CMC -
Alex DePaoli,
Senior Vice President, Chief Translational Officer -
Valerie Pierce,
Senior Vice President, Chief Compliance Officer, General Counsel, Secretary -
Dr. Hsiao Dee Lieu,
Chief Medical Officer & Sr. VP -
Brian Muma,
VP of HR -
Valerie L. Pierce J.D.,
Sr. VP, Gen. Counsel, Sec. & Chief Compliance Officer -
Alexander Duke Schwartz,
Exec. Director of Investor Relations -
Group L Ptcg Opportunity Ii...,
-
Group L Pcolumn Group Gp, L...,
-
Group L Pcolumn Group Gp, L...,
-
Group L P Svennilson Peter ...,
-
Peter Svennilson,
Director -
Group L Pcolumn Group Ii, L...,
-
Group L Pcolumn Group Iii, ...,
-
Aetna Wun Trombley,
President & COO -
Group L Pcolumn Group Ii, L...,
-
Group L Pcolumn Group Ii, L...,
-
Group L P Ponoi Capital Ii,...,
-
Group L Pcolumn Group Iii, ...,
-
Roger M Perlmutter,
-
Group L Pcolumn Group Gp, L...,
-
Group L Pcolumn Group Iii, ...,
-
Jean Frederic Viret,
Chief Financial Officer -
Group Gp, Lpcolumn Group Ii...,
-
Opportunity Iii Gp, Llc Tcg,
10% owner -
Irene Perlich,
Principal Accounting Officer